EUVIMEDEUVIMED entdecken
Open Access

De novo design and structure of a peptide–centric TCR mimic binding module

Karsten D Householder iD, Xinyu Xiang iD, Kevin M Jude iD, Arthur Deng, Matthias Obenaus iD, Yang Zhao iD, Steven C Wilson iD, Xiaojing Chen iD, Nan Wang iD, K Christopher Garcia iD

Science · 24.07.2025 · 389 (6758) · 375-379

DOI: 10.1126/science.adv3813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 24.07.2025. Verfasst von Karsten D Householder und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Antigens, Neoplasm, HLA-A2 Antigen, Membrane Proteins, Peptides. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, Howard Hughes Medical Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell receptor (TCR) mimics offer a promising platform for tumor-specific targeting of peptide–major histocompatibility complex (pMHC) in cancer immunotherapy. In this study, we designed a de novo α-helical TCR mimic (TCRm) specific for the NY-ESO-1 peptide presented by human leukocyte antigen (HLA)–A*02, achieving high on-target specificity with nanomolar affinity (dissociation constant K d = 9.5 nM). The structure of the TCRm-pMHC complex at 2.05-Å resolution revealed a rigid TCR-like docking mode with an unusual degree of focus on the up-facing NY-ESO-1 side chains, suggesting the potential for reduced off-target reactivity. Indeed, a structure-informed in silico screen of 14,363 HLA-A*02 peptides correctly predicted two off-target peptides, yet our TCRm maintained peptide selectivity and cytotoxicity as a T cell engager. These results represent a path for precision targeting of tumor antigens with peptide-focused α-helical TCR mimics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmHLA-A2 AntigenMembrane ProteinsPeptidesReceptors, Antigen, T-CellMolecular MimicryHumansImmunotherapyMolecular Docking SimulationNeoplasmsProtein BindingProtein Conformation, alpha-HelicalProtein Engineering

Substanzen

Antigens, NeoplasmCTAG1B protein, humanHLA-A2 AntigenMembrane ProteinsPeptidesReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
  • Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Computer Science, Stanford University, Stanford, CA, USA.
  • Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.

ORCID-Profile: Karsten D Householder, Xinyu Xiang, Kevin M Jude, Matthias Obenaus, Yang Zhao, Steven C Wilson, Xiaojing Chen, Nan Wang, K Christopher Garcia

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • Howard Hughes Medical Institute

Zitieren

APA

Householder, K. D., Xiang, X., Jude, K. M., Deng, A., Obenaus, M., Zhao, Y., Wilson, S. C., Chen, X., Wang, N., & Garcia, K. C. (2025). De novo design and structure of a peptide–centric TCR mimic binding module. Science, 389(6758), 375-379. https://doi.org/10.1126/science.adv3813

Vancouver

Householder KD, Xiang X, Jude KM, Deng A, Obenaus M, Zhao Y, et al. De novo design and structure of a peptide–centric TCR mimic binding module. Science. 2025;389(6758):375-379. doi:10.1126/science.adv3813

BibTeX
@article{Householder2025,
  author = {Householder, Karsten D and Xiang, Xinyu and Jude, Kevin M and Deng, Arthur and Obenaus, Matthias and Zhao, Yang and Wilson, Steven C and Chen, Xiaojing and Wang, Nan and Garcia, K Christopher},
  title = {De novo design and structure of a peptide–centric TCR mimic binding module},
  journal = {Science},
  year = {2025},
  volume = {389},
  number = {6758},
  pages = {375--379},
  doi = {10.1126/science.adv3813}
}
Kostenlos starten →